Skip to main content
. Author manuscript; available in PMC: 2017 Jul 27.
Published in final edited form as: Clin Trials. 2012 Apr 30;9(3):303–313. doi: 10.1177/1740774512443593

Figure 2.

Figure 2

From left to right: pseudodata CR 1 is utilized in scenarios A, C, and E and has a starting dose of 1060 mg for a 30% DLT rate. Pseudodata CR 2 is utilized in scenarios B, D, and F and has a starting dose equal to 2145 mg for a 30% DLT rate.

DLT: dose-limiting toxicity; CR: continuation ratio.